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Bier blockAbstract Objective: This study was designed to evaluate the effect of adding ultra-low dose of
naloxone as an adjuvant to lidocaine for intravenous regional anesthesia (IVRA).
Method: Forty patients undergoing elective short procedures in the upper limb were randomly and
blindly divided into two groups of twenty patients each. Group L (n= 20) received 3 mg/kg of 2%
lidocaine diluted with normal saline to 30 ml. Group LN (n= 20) received 3 mg/kg of 2% lidocaine
and naloxone 100 ng (1 ml) diluted with normal saline to 30 ml. Onset and recovery time of sensory
and motor block, intraoperative and post-operative pain were measured by visual analog score
(VAS), and also intraoperative analgesic requirement, time of first requirement of diclofenac post-
operatively, total amount of diclofenac needed in 24 h, patient’s satisfaction and surgeon’s satisfac-
tion scores were measured.
Results: Recovery of sensory block was significantly longer in group LN (26.7 ± 2.8 min) com-
pared to group L (16.3 ± 0.6 min); p value (0.000). Also the recovery of motor block was signifi-
cantly longer in group LN (19.1 ± 1.0 min) compared to group L (17.9 ± 1.2 min), p value
(0.002). Intraoperative fentanyl requirement was significantly less in group LN (15.8 ± 5.0 mcg)
compared to group L (40.0 ± 10.5 mcg), p value (0.000). 1st fentanyl requirement time was signif-
icantly longer in group LN (22.4 ± 3.1 min) than in group L (14.5 ± 6.1 min), p value (0.000).
Time of first analgesic requirement post-operative was longer in group LN (78.5 ± 6.8 min) com-
pared to group L (40.5 ± 2.0 min), p value (0.000). Total amount of diclofenac needed in 24 h was
significantly less in group LN (57 ± 50 mg) compared to group L (120 ± 45 mg), p value (0.000).
Conclusion: The addition of ultra-low-dose naloxone 100 ng to lidocaine for IVRA in upper limb
surgery, prolonged the duration of sensory and motor block, and reduced tourniquet pain, as well
as intraoperative and postoperative analgesic consumption.
 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
IVRA is simple, reliable, and cost-effective, with a success rate
varying between 94% and 98% [1,2]. It is a favorable choice
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around one hour. However there are some concerns associated
with IVRA such as tourniquet pain, inadequate muscle
relaxation, insufficient postoperative analgesia and local anes-
thetic toxicity [2].
Naloxone has proved to have paradoxical effects as it
antagonizes the opioid analgesia if given in high doses (micro-
gram range) and produces anti-nociceptive effect if given in
ultra-low doses (nanogram range) [3,4]. Different mechanisms
have explained the effect of ultra-low dose naloxone including
selective inhibition of the impulses from excitatory opioid
receptors and release of enkephalin [5–8]. It has been used
safely via the epidural and intrathecal routes for reducing opi-
oids side effects or enhancing analgesia [9,10]. Also it was
added to fentanyl and lidocaine for peri-bulbar anesthesia
and prolonged the duration of postoperative analgesia without
side effects [11].
We designed this study to evaluate the effect of adding
ultra-low dose of naloxone to lidocaine for IVRA for elective
short procedures in the upper limb. Our primary outcome was
the time for first analgesic requirement (diclofenac). Secondary
outcomes included the onset and recovery of sensory block,
onset and recovery of motor block, intraoperative fentanyl
requirement, time of first fentanyl requirement, intraoperative
and post-operative VAS, total amount of diclofenac used in
24 h, and surgeon’s and patient’s satisfaction.2. Methods
After obtaining ethical committee approval and written
informed consent, forty patients with American Society ofFigure 1 ParticipAnesthesiologists (ASA) I or II, between 20 and 60 years
old; who were scheduled for short elective procedures for the
hand and forearm; were included in our prospective, random-
ized, double blind study done at Saad Specialist Hospital,
Saudi Arabia; between June 2014 and December 2014. Patients
who have history of allergy to the study drugs, uncooperative
patients, patients with open wounds and infection of the oper-
ative limb, patients with peripheral arterial disease, or sickle
cell disease, patients received analgesia in the previous 24 h,
and pregnant women were excluded from the study. Patients
were randomly allocated into two groups of twenty patients
each (Fig. 1). Group L (n= 20) received 3 mg/kg of 2% lido-
caine diluted with normal saline to 30 ml. Group LN (n= 20)
received 3 mg/kg of 2% lidocaine and naloxone 100 ng (1 ml)
diluted with normal saline to 30 ml. Our patients were ran-
domly allocated into two equal groups (20 patients each)
according to a computer-generated table of random numbers
(Excel, Microsoft, Inc., Redmond, Washington, USA). Study
medications were prepared by a pharmacist who was not par-
ticipating in the study; according to the table of randomiza-
tion. The anesthesiologists were supplied with identical
syringes with a code number given by the pharmacist. The
anesthesiologist, investigator, surgeon and the patients were
blinded to the study medications.
All patients were requested to be fasting for 8 h before
operation, and the IVRA technique was explained to them pre-
operatively. On arrival to the operating room two intra-venous
accesses were inserted, one in the non-operative side for intra-
venous fluid infusion and any needed medications and the
second one in the operative side inserted in a distal vein in
the dorsum of the hand for injection of the study medications
for IVRA and was removed immediately after the block.ant flowchart.
Table 1 Demographic and intraoperative data.
Data Group L
(n= 20)
Group LN
(n= 20)
P value
Age (years) 37.8 ± 3.7 38.1 ± 2.4 0.763
Weight (kg) 67.4 ± 4.5 66.3 ± 6.4 0.534
Gender (m/f) 9/11 10/10 1.0
Duration of surgery (min) 36.0 ± 4.7 35.7 ± 7.5 0.880
Time of tourniquet
application (min)
43.1 ± 3.2 42.3 ± 2.5 0.384
Type of surgery
(carpal tunnel, ganglion
excision, tendon release,
trigger finger)
7/7/4/2 8/7/3/2 0.976
Values are expressed as mean ± SD and numbers.
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and noninvasive blood pressure were applied.
All patients were pre-medicatedwith intravenousmidazolam
(0.05 mg/kg) 10 min before the block.After exsanguinationwith
an Esmarch bandage, double-cuff pneumatic tourniquet was
applied at the upper arm and the proximal cuff was inflated to
a pressure of at least 100 mmHg more than baseline systolic
blood pressure or a minimum of 250 mmHg to occlude the
circulation to the arm which was confirmed by the absence of
radial pulse and failure of pulse oximetry tracing in the fingers
of the same side, followed by injection of 30 ml of test solution
over one minute. The distal tourniquet was inflated 10 min after
the injection of the test medications and then the proximal
tourniquet was deflated. After the injection of the test
medications, the onset of sensory block was checked by the
pin prick method, with a 22G hypodermic needle every 30 s in
the sensory distribution of the median, ulnar, and radial nerves.
Sensory block onset time was defined as the time from injection
of the test drug until sensory block in all dermatomes distal to
the tourniquet. The motor block was tested every one min until
the patient was not able to flex or extend the wrist or move his
fingers.Motor block onset time was considered as the time from
injection of the test drug until the patient is unable to do
any movement. Cyclic deflation technique was used for
tourniquet deflation after at least 40 min and was not inflated
for more than 1.5 h.
Intraoperatively; heart rate, blood pressure, and oxygen sat-
uration were measured every 5 min. Intra-operative tourniquet
pain was assessed every 15 min using VAS of (0–10); 0 means
no pain and 10meansworst imaginable pain and if was recorded
>3; fentanyl 25mcg was given intravenously. The first fentanyl
requirement time and the total amount of fentanyl given to the
patient were recorded.
Post operatively, pain was measured using VAS at 0, 15, 30,
60, 120, 180, 240 and 360 min. For VAS >3, diclofenac 75 mg
intramuscular was given every 12 h if needed. The time from
the release of distal tourniquet till the sensation of a sharp pain
at the surgical site was considered as the time of return of
sensation. The time from the release of distal tourniquet to
the time at which patients were able to move their wrist was
considered as the time of return of motor power.
Time for first dose diclofenac given to the patient is the time of
first analgesic requirement and total dose of diclofenac consumed
in 24 h were recorded. Postoperative complications as tinnitus and
convulsions were noted. Patient’s satisfaction score for the anes-
thetic technique was also recorded according to the numeric score:
3 = good (no complaint from patient), 2 = moderate (minor
complaint with no need for analgesics), and 1 = poor (complaint
which required supplemental analgesics). The surgeon, who was
blinded to the givenmedication, was asked to qualify the operative
condition according to the following numeric scale: 1 = unsuc-
cessful, 2 = poor, 3 = acceptable and 4 = perfect.
Sample size was calculated according to the time for first
analgesic requirement (primary outcome); to reach a signifi-
cant difference between both groups by accepting an alpha risk
of 5% and a power of 99% (1  b), twenty patients were
needed in each group for a significant difference (p< 0.05).
We considered clinical significant benefit of using ultra low-
dose naloxone as an adjuvant to lidocaine for IVRA; if it leads
to 15% prolongation in the time of first analgesic requirement
needed if lidocaine was used alone [12].2.1. Statistical analysis
Data were statistically described in terms of mean ± standard
deviation (±SD), or frequencies (number of cases). Compar-
ison of numerical variables between the study groups was done
using Student’s t test for independent samples in comparing
normally distributed data and Mann Whitney U test for inde-
pendent samples when data were not normally distributed. For
comparing categorical data, Chi square (v2) test was per-
formed. Exact test was used instead when the expected fre-
quency is less than 5. P values less than 0.05 were considered
statistically significant. All statistical calculations were done
using computer program Statistical Package for the Social
Science (SPSS Inc., Chicago, IL, USA) release 15 for Micro-
soft Windows (2006).
3. Results
Demographic data and intraoperative data including age,
weight, gender, duration of surgery, time of tourniquet appli-
cation and type of surgery were comparable in both groups
(Table 1).
The block characteristics are shown in Table 2. Time of
onset of sensory and motor block was comparable in both
groups, but the recovery of sensory block was significantly
longer in group LN (26.7 ± 2.8 min) compared to group L
(16.3 ± 0.6 min); p value (0.000). Also the recovery of motor
block was significantly longer in group LN (19.1 ± 1.0 min)
compared to group L (17.9 ± 1.2 min), p value (0.002). Intra-
operative fentanyl requirement was significantly less in group
LN (15.8 ± 5.0 mcg) compared to group L (40.0 ± 10.5
mcg), p value (0.000). First fentanyl requirement time was
significantly longer in group LN (22.4 ± 3.1 min) than in
group L (14.5 ± 6.1 min), p value (0.000). Time of first anal-
gesic requirement post-operative was significantly longer in
group LN (78.5 ± 6.8 min) compared to group L (40.5
± 2.0 min), p value (0.000). Total amount of diclofenac
needed in 24 h was significantly less in group LN (57
± 50 mg) compared to group L (120 ± 45 mg), p value
(0.000).
Table 3 demonstrates the intraoperative and postoperative
VAS in both groups.
The complications, patients’ satisfaction and surgeon’s sat-
isfaction score are shown in Table 4.
Table 2 The block characteristics in both groups.
Data Group L
(n= 20)
Group LN
(n= 20)
Onset of sensory block (min) 6.3 ± 2.0 6.1 ± 1.5 0.732
Recovery of sensory block
(min)
16.3 ± 0.6 26.7 ± 2.8 0.000*
Onset of motor block (min) 11.3 ± 1.0 10.8 ± 2.5 0.414
Recovery of motor block
(min)
17.9 ± 1.2 19.1 ± 1.0 0.002*
Intraoperative fentanyl
requirement (mcg)
40.0 ± 10.5 15.8 ± 5.0 0.000*
First fentanyl requirement
time (min)
14.5 ± 6.1 22.4 ± 3.1 0.000*
Time of first analgesic
requirement post op
40.5 ± 2.0 78.5 ± 6.8 0.000*
Total amount of diclofenac
(mg)
120 ± 45 57 ± 50 0.000*
Values are expressed as mean ± SD.
* means p value < 0.05.
Table 3 Intraoperative and postoperative VAS.
Data Group L
(n= 20)
Group LN
(n= 20)
Before tourniquet inflation 0 0
After 15 min 1.1 ± 0.2 0.9 ± 1.1 0.433
After 30 min 2.5 ± 0.7 1.2 ± 1.2 0.000*
After 45 min 2.7 ± 1.0 1.8 ± 1.0 0.007
Immediately after tourniquet
release
2.7 ± 1.0 1.8 ± 1.0 0.007
15 min after release of
tourniquet
3.2 ± 1.9 1.9 ± 1.7 0.028*
30 min after release of
tourniquet
3.1 ± 1.8 2.3 ± 1.8 0.168
60 min after release of
tourniquet
3.2 ± 1.0 2.9 ± 1.9 0.537
120 min after release of
tourniquet
3.3 ± 1.2 3.0 ± 0.8 0.359
180 min after release of
tourniquet
3.5 ± 1.3 3.1 ± 0.6 0.233
240 min after release of
tourniquet
2.9 ± 1.2 2.0 ± 0.9 0.011*
360 min postop 2.9 ± 1.6 2.2 ± 2.0 0.230
Values are expressed as mean ± SD.
* means p value < 0.05.
Table 4 Complications, patients’ satisfaction and surgeon’s
satisfaction score.
Data Group L
(N= 20)
Group LN
(N= 20)
P
value
Tinnitus 0 0
Convulsions 0 0
Patients’ satisfaction
(1/2/3)
(2/2/16) (1/0/19) 0.274
Surgeon’s satisfaction
(1/2/3/4)
(0/1/2/17) (0/0/2/18) 0.976
Values are expressed as numbers.
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The results of our study revealed that addition of ultra-
low-dose naloxone to lidocaine for IVRA prolonged the
duration of sensory and motor block, and reduced tourniquet
pain, as well as intraoperative and postoperative analgesic
consumption.
The antinociceptive effect of ultra-low dose naloxone was
explained 20 years ago by Crain and Shen, who demonstrated
that naloxone and naltrexone have selective antagonistic
effects on the excitatory opioid receptor functions, unmasking
the inhibitory effects of morphine and other opioids acting onmu (l) delta (d) and kappa (j) receptors and cause prolonga-
tion of the Ca2 + dependent component of the action poten-
tial [5].
Naloxone interferes with the transient switch in G-protein
coupling by l-opioid receptor from Gi/o to Gs and reduces
the opioid tolerance and dependence by the high-affinity inter-
action of naloxone to a penta-peptide area in c-terminal fil-
amin A (FLNA) interacting with l-opioid receptors [13].
Also, low dose naloxone has been shown to release endor-
phins, or displaces endorphins from receptor sites [14].
The release of enkephalin which is an endorphin is con-
trolled by a presynaptic autoregulatory system. Large amount
of enkephalins results in negative feedback, reducing further
release. Naloxone, given as an ultra-low-dose infusion, blocks
this negative feedback and enhances analgesia from enkepha-
lins [4,15,16]; this could also explain its antipronociceptive
effect.
Previous studies in both animal and human models sug-
gested that naloxone produces a dose-dependent pain
response. In rats, small doses of naloxone resulted in paradox-
ical analgesia, whereas larger doses caused hyperalgesia
[4,16,17].
Movafegh et al. studied the effect of adding ultra-low-dose
naloxone to lidocaine with or without fentanyl in axillary bra-
chial plexus block and they revealed that ultra-low-dose nalox-
one prolongs the time to first post-operative pain, which is
consistent with our results [18].
Also Gan et al. reported that an ultra-low dose naloxone
infusion (0.25 ug/kg/h) enhanced morphine analgesia and
reduced postoperative narcotic requirement after abdominal
hysterectomies [14].
Similarly, Gordon et al. found that the use of low-dose
naloxone and nalbuphine resulted in good pain control and
no significant side effects after gynecological operations and
even some patients did not require any rescue medication [19].
Hamann and Sloan reported a case of a patient with severe
chronic low back pain post-laminectomy operation used
intrathecal low dose 20 gg naloxone added to intrathecal mor-
phine 2 mg bolus and 5 mg morphine and 50 gg naloxone
intrathecally as infusion daily for 3 years and reported that
the patient maintained pain reduction of 60–80% and returned
to daily activities and no further hospitalization [20].
On the other hand, some studies failed to report the effect of
ultra-low dose opioid antagonist in preventing opioid-induced
side effects or to augment analgesia and this may be related to
how the opioid antagonist was prepared and administered to
the patients. In all these studies in which the antagonist was
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given through a PCA pump [21,22]. This might result in only
small doses of naloxone intermittently given to the patients
when the PCA pump was triggered. Also, naloxone and mor-
phine may be incompatible when in a solution for a prolonged
period.
The onset of sensory and motor block in our study was
similar in both groups. On the contrary Movafegh et al. [18]
reported prolongation of the onset time in the sensory and
motor block in their naloxone group, but they stated that it
was not clinically significant.
There was no difference in the patient’s satisfaction score or
surgeon’s satisfaction score, and a larger sample size might be
needed to detect a difference in the satisfaction of both patients
and surgeons.
Limitation to our study is that we used only one concentra-
tion of naloxone (100 ng); other naloxone concentrations
(smaller and larger doses) should be evaluated to determine
the optimum dose of naloxone as adjuvant to lidocaine in
IVRA.
In conclusion, the addition of ultra-low-dose naloxone
100 ng to lidocaine for IVRA in upper limb surgery prolonged
the duration of sensory and motor block, and reduced
tourniquet pain, as well as intraoperative and postoperative
analgesic consumption.
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